AZD-8309

AZD-8309 (AZD8309) is a potent and orally bioavailable CXCR2 antagonist that has been proposed to regulate the transmigration of neutrophils; significantly reduces MPO in the pancreas and lungs, and reduces intrapancreatic trypsin and elastase activity in caerulein-pancreatitis; also reduces cathepsin B activity and MPO in taurocholate-pancreatitis; also antagonises the CCR2b receptor but it is 10-fold less potent than at CXCR2. COPD Phase 1 Clinical

References 1. Virtala R, et al. Clin Exp Allergy. 2012 Apr;42(4):590-6. 2. Leaker BR, et al. Respir Res. 2013 Dec 16;14:137. 3. Malla SR, et al. Pancreatology. 2016 Sep-Oct;16(5):761-9. View Related Products by Target Chemokine Receptor (CCR and CXCR) COPD